257 related articles for article (PubMed ID: 19117999)
1. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.
Huang F; Greer A; Hurlburt W; Han X; Hafezi R; Wittenberg GM; Reeves K; Chen J; Robinson D; Li A; Lee FY; Gottardis MM; Clark E; Helman L; Attar RM; Dongre A; Carboni JM
Cancer Res; 2009 Jan; 69(1):161-70. PubMed ID: 19117999
[TBL] [Abstract][Full Text] [Related]
2. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.
Haluska P; Carboni JM; TenEyck C; Attar RM; Hou X; Yu C; Sagar M; Wong TW; Gottardis MM; Erlichman C
Mol Cancer Ther; 2008 Sep; 7(9):2589-98. PubMed ID: 18765823
[TBL] [Abstract][Full Text] [Related]
3. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model.
Huang F; Hurlburt W; Greer A; Reeves KA; Hillerman S; Chang H; Fargnoli J; Graf Finckenstein F; Gottardis MM; Carboni JM
Cancer Res; 2010 Sep; 70(18):7221-31. PubMed ID: 20807811
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
Scotlandi K; Manara MC; Nicoletti G; Lollini PL; Lukas S; Benini S; Croci S; Perdichizzi S; Zambelli D; Serra M; García-Echeverría C; Hofmann F; Picci P
Cancer Res; 2005 May; 65(9):3868-76. PubMed ID: 15867386
[TBL] [Abstract][Full Text] [Related]
5. Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.
Hou X; Huang F; Carboni JM; Flatten K; Asmann YW; Ten Eyck C; Nakanishi T; Tibodeau JD; Ross DD; Gottardis MM; Erlichman C; Kaufmann SH; Haluska P
Mol Cancer Ther; 2011 Jan; 10(1):117-25. PubMed ID: 21220496
[TBL] [Abstract][Full Text] [Related]
6. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy.
Litzenburger BC; Creighton CJ; Tsimelzon A; Chan BT; Hilsenbeck SG; Wang T; Carboni JM; Gottardis MM; Huang F; Chang JC; Lewis MT; Rimawi MF; Lee AV
Clin Cancer Res; 2011 Apr; 17(8):2314-27. PubMed ID: 21177763
[TBL] [Abstract][Full Text] [Related]
7. Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas.
Potratz JC; Saunders DN; Wai DH; Ng TL; McKinney SE; Carboni JM; Gottardis MM; Triche TJ; Jürgens H; Pollak MN; Aparicio SA; Sorensen PH
Cancer Res; 2010 Nov; 70(21):8770-81. PubMed ID: 20959493
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.
Law JH; Habibi G; Hu K; Masoudi H; Wang MY; Stratford AL; Park E; Gee JM; Finlay P; Jones HE; Nicholson RI; Carboni J; Gottardis M; Pollak M; Dunn SE
Cancer Res; 2008 Dec; 68(24):10238-46. PubMed ID: 19074892
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
Browne BC; Eustace AJ; Kennedy S; O'Brien NA; Pedersen K; McDermott MS; Larkin A; Ballot J; Mahgoub T; Sclafani F; Madden S; Kennedy J; Duffy MJ; Crown J; O'Donovan N
Breast Cancer Res Treat; 2012 Dec; 136(3):717-27. PubMed ID: 23117852
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
Haluska P; Carboni JM; Loegering DA; Lee FY; Wittman M; Saulnier MG; Frennesson DB; Kalli KR; Conover CA; Attar RM; Kaufmann SH; Gottardis M; Erlichman C
Cancer Res; 2006 Jan; 66(1):362-71. PubMed ID: 16397250
[TBL] [Abstract][Full Text] [Related]
11. IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines.
Huang F; Chang H; Greer A; Hillerman S; Reeves KA; Hurlburt W; Cogswell J; Patel D; Qi Z; Fairchild C; Ryseck RP; Wong TW; Finckenstein FG; Jackson J; Carboni JM
Mol Cancer Ther; 2015 Feb; 14(2):620-30. PubMed ID: 25527633
[TBL] [Abstract][Full Text] [Related]
12. BMS-754807, a small-molecule inhibitor of insulin-like growth factor-1 receptor/insulin receptor, enhances gemcitabine response in pancreatic cancer.
Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
Mol Cancer Ther; 2012 Dec; 11(12):2644-53. PubMed ID: 23047891
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers.
Ohashi H; Adachi Y; Yamamoto H; Taniguchi H; Nosho K; Suzuki H; Arimura Y; Imai K; Carbone DP; Shinomura Y
Cancer Sci; 2012 Feb; 103(2):252-61. PubMed ID: 22044563
[TBL] [Abstract][Full Text] [Related]
14. Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.
Wahner Hendrickson AE; Haluska P; Schneider PA; Loegering DA; Peterson KL; Attar R; Smith BD; Erlichman C; Gottardis M; Karp JE; Carboni JM; Kaufmann SH
Cancer Res; 2009 Oct; 69(19):7635-43. PubMed ID: 19789352
[TBL] [Abstract][Full Text] [Related]
15. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
[TBL] [Abstract][Full Text] [Related]
16. BMS-536924 reverses IGF-IR-induced transformation of mammary epithelial cells and causes growth inhibition and polarization of MCF7 cells.
Litzenburger BC; Kim HJ; Kuiatse I; Carboni JM; Attar RM; Gottardis MM; Fairchild CR; Lee AV
Clin Cancer Res; 2009 Jan; 15(1):226-37. PubMed ID: 19118050
[TBL] [Abstract][Full Text] [Related]
17. Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma.
Garofalo C; Mancarella C; Grilli A; Manara MC; Astolfi A; Marino MT; Conte A; Sigismund S; Carè A; Belfiore A; Picci P; Scotlandi K
Mol Endocrinol; 2012 Sep; 26(9):1603-16. PubMed ID: 22798295
[TBL] [Abstract][Full Text] [Related]
18. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.
Carboni JM; Wittman M; Yang Z; Lee F; Greer A; Hurlburt W; Hillerman S; Cao C; Cantor GH; Dell-John J; Chen C; Discenza L; Menard K; Li A; Trainor G; Vyas D; Kramer R; Attar RM; Gottardis MM
Mol Cancer Ther; 2009 Dec; 8(12):3341-9. PubMed ID: 19996272
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
[TBL] [Abstract][Full Text] [Related]
20. Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
Buck E; Eyzaguirre A; Rosenfeld-Franklin M; Thomson S; Mulvihill M; Barr S; Brown E; O'Connor M; Yao Y; Pachter J; Miglarese M; Epstein D; Iwata KK; Haley JD; Gibson NW; Ji QS
Cancer Res; 2008 Oct; 68(20):8322-32. PubMed ID: 18922904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
